Denali | Home
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative and lysosomal storage diseases …
Denali | Defeat Degeneration
Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Denali | Frontotemporal Dementia (FTD) Clinical Program
Learn about Denali's Frontotemporal dementia (FTD) program. Frontotemporal dementia (FTD) associated with a mutation in the GRN (granulin) gene, referred to as FTD-GRN, is primarily …
Denali | Sanfilippo Syndrome (MPS III A) Clinical Program
Denali’s scientific approach to Sanfilippo syndrome Type A. Denali is evaluating DNL126 in a clinical study. This treatment is proposed to work by using Enzyme Transport Vehicle (ETV) …
Leadership - Denali
Success is accelerated by experience, collaboration and leadership. Denali’s Board of Directors combines expertise across industry, academia, drug development and the investment …
Denali | Expanded Access Policy (EAP)
Denali Therapeutics believes that the goal of making life-changing medicines available to the patient community is achieved through well-designed clinical studies followed by regulatory …
Denali has reported a greater than 90% mean reduction in CSF heparan sulfate at week 24 of treatment, remaining unchanged at week 104. Directly correlating the biomarker with clinical …
Engineering Brain Delivery - Denali
Delivering therapeutics across the BBB has been a major obstacle to successful drug development in neurodegeneration, and is critical to enabling effective treatments.
Contact - Denali
Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development
Pipeline - Denali
Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.